Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $509.55 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Judy D. Olian, a Director at United Therapeutics Corp (UTHR), reported a sale of 200 shares of common stock.
• The transaction occurred on February 27, 2026, at a price of $509.55 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which was established on November 24, 2025.
• Following this transaction, Ms. Olian beneficially owns 4,845 shares of United Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine disclosure of a pre-planned transaction by a director and involves a relatively small number of shares, thus having minimal impact on overall sentiment.

Positives

• The sale was conducted under a pre-arranged 10b5-1 plan, indicating a non-discretionary transaction and reducing the perception of opportunistic insider selling.

Negatives

• A director's sale of common stock, even if pre-planned, can sometimes be interpreted by investors as a minor signal, though the small volume of 200 shares limits its significance.

Risks

• While minor, any insider sale could potentially lead to slight negative investor sentiment if misinterpreted as a lack of confidence, despite the pre-arranged nature of the transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those executed under 10b5-1 plans, are common across all industries and typically do not reflect broader industry trends or competitive positioning. This specific transaction is a standard disclosure for a director's planned equity sale.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a director, even under a 10b5-1 plan, might be noted by shareholders but is unlikely to significantly alter their investment thesis given the routine nature and small volume.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction